Merck Sharp + Dohme Corp.

Schering Corporation

Biogen Ma Inc.

Alissa A Chackerian

Robert A Kastelein

Juha Punnonen

Luigina Romani

Drake LaFace

Manfred Kopf

Jeffery Grein

Smita Mauze

Lakshmanan Annamalai

Anandi Sawant

Edward Bowman

David Bauche

Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.

Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents

Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels

Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.

Use of IL-23 antagonists for treatment of infection

Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.

Method of treating asthma or allergy by administering an IL-33 receptor antibody

IL-33 receptor

Growing community of inventors

Sunnyvale, CA, United States of America

Alissa A Chackerian